Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NanosonicsNNCSF 84 Cash-to-Debt is 23.95 as of Dec. 2025, which is 24% below its 10-year median of 31.51. GuruFocus rates NNCSF with a GF Score™ of 84/100 and a GF Value™ of $3.52 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 812 Medical Devices & Instruments companies, Nanosonics ranks better than 81.65% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nanosonics's cash to debt ratio for the quarter that ended in Dec. 2025 was 23.95.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nanosonicscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Nanosonics's Cash-to-Debt or its related term are showing as below:
NNCSF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 8.07 Med: 31.51 Max: 138.54
Current: 23.95
During the past 13 years, Nanosonics's highest Cash to Debt Ratio was 138.54. The lowest was 8.07. And the median was 31.51.
NNCSF's Cash-to-Debt is ranked better than 81.65% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs NNCSF: 23.95
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Nanosonics Cash-to-Debt Related Terms
Nanosonics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Nanosonics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Nanosonics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Nanosonics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a Cash-to-Debt of 23.95 as of Dec. 2025. This is 24% below median its historical median of 31.51. Over the past decade, Nanosonics' Cash-to-Debt has ranged from 8.07 to 138.54. According to the industry distribution chart, Nanosonics ranks #149 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 18.3%.
Is Nanosonics' Cash-to-Debt too high?
Nanosonics' current Cash-to-Debt of 23.95 is 24% below median its 10-year median of 31.51. Over the past 10 years, this metric has ranged from a low of 8.07 to a high of 138.54. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Nanosonics' value of 23.95 is 1325.6% above this industry median. Based on the distribution chart, Nanosonics ranks #149 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanosonics has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #149 out of 812 companies for Cash-to-Debt. This places Nanosonics in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.68. Nanosonics' value of 23.95 is 1325.6% above this benchmark. Historically, Nanosonics' own Cash-to-Debt has ranged from 8.07 to 138.54 over the past decade. While the company's 10-year median is 31.51 vs. the industry median of 1.68, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Cash-to-Debt of 23.95 is 1325.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Cash-to-Debt is 23.95, which is 24% below median its own 10-year median of 31.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.52, compared to a current price of $2.30 — trading 34.7% below its estimated fair value. The current Cash-to-Debt is 23.95, which is 24% below median its 10-year median of 31.51 and 1325.6% above the Medical Devices & Instruments industry median of 1.68. Nanosonics' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Cash-to-Debt is 23.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.30 is trading 34.7% below its estimated GF Value™ of $3.52.
GuruFocus considers Nanosonics to be Significantly Undervalued.
Key valuation signals for NNCSF:
Cash-to-Debt: 23.95 (24% below median its 10-year median of 31.51)
GF Value™: $3.52 vs. price of $2.30 (34.7% below fair value)
Industry Position: 1325.6% above the Medical Devices & Instruments median (#149 of 812)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
84GF Score
Get the complete analysis for NNCSF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
